1. U.S. Food and Drug Administration.Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs.https://www.fda.gov/media/71372/download. Published October2005. Accessed December 20 2021.
2. Cardiac safety investigations 10 years after ICH guidance E14: evolving industry and regulatory viewpoints on evaluation of proarrhythmic risk during new drug development;Kothari S;J Clin Stud,2015
3. European Medicines Agency.ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs (R3) ‐ questions and answers.https://www.ema.europa.eu/en/documents/scientific‐guideline/ich‐guideline‐e14‐clinical‐evaluation‐qt/qtc‐interval‐prolongation‐proarrhythmic‐potential‐non‐antiarrhythmic‐drugs‐r3‐questions‐answers‐step_en.pdf. Published January 25 2016. Accessed December 20 2021.
4. Arrhythmias Seen in Baseline 24-Hour Holter ECG Recordings in Healthy Normal Volunteers During Phase 1 Clinical Trials
5. Baseline and new-onset morphologic ECG abnormalities in healthy volunteers in phase I studies receiving placebo: Changes over a 6-week follow-up period